Akeso announced that the first patient has been dosed in a Phase II clinical study (AK146D1-201) of its TROP2/Nectin-4 bispecific ADC (AK146D1) combined with Ivonescimab for advanced NSCLC. The trial tests a novel bispecific ADC-immunotherapy combination that could address unmet needs in NSCLC and strengthen Akeso’s pipeline, with potential implications for competitive positioning and future licensing deals. Who is involved: Akeso, Inc. (9926.HK) as sponsor; Ivonescimab as the partner immuno‑oncology agent; clinical sites enrolling patients with advanced NSCLC.. Likely next: Interim safety and efficacy data are expected in the second half of 2027; positive outcomes could trigger a Phase III program and regulatory discussions with the FDA/EMA in 2028.. Akeso dosed the first patient in a Phase II study evaluating AK146D1, its internally developed TROP2/Nectin-4 antibody-drug conjugate, in combination with the anti‑PD‑L1 antibody Ivonescimab for advanced non‑small cell lung cancer. The trial marks a step forward in the company’s strategy to develop targeted ADCs for solid tumors and to explore immunotherapy‑ADC combinations. Success could differentiate Akeso’s offering in a crowded NSCLC therapeutics landscape and potentially attract partnership interest. Likely next events: Interim efficacy and safety data from AK146D1-201 expected H2 2027 If positive, Akeso may initiate a Phase III trial in 2028 Potential regulatory discussions with FDA/EMA on bispecific ADC pathway in 2028 Sectors affected: Oncology Biopharmaceutical ADC development NSCLC therapeutics Regulatory implications: FDA may require separate safety assessment for the bispecific ADC construct EMA likely to request biomarker‑driven subgroup analysis for TROP2/Nectin-4 expression Combination with Ivonescimab may trigger additional review of immuno‑oncology combo guidance Historical parallels: Approval of Enhertu (fam‑trastuzumab deruxtecan) for HER2‑low breast cancer 2020 demonstrated ADC success in solid tumors Sacituzumab govitecan approval for metastatic triple‑negative breast cancer 2021 showed ADC plus chemotherapy benefit
INTELLIGENCE
Social Pulse
AI estimate · not scraped